CMS pushes ahead with AMD (age-related macular degeneration) policy:
This article was originally published in Clinica
Executive Summary
New US reimbursement policy for a procedure to treat the occult form of wet age-related macular degeneration (AMD) is proceeding, says the US Vitreous Society, an association specialising in retinal diseases. The society, which requested the change late last month, says the new policy is being implemented cautiously, as the drug in question, Visudyne (verteporfin), has not yet gained US approval for the indication (see Clinica No 981, p 11). The procedure involves using the drug in combination with a laser. The therapy has been designed by Novartis Ophthalmics (Atlanta, Georgia) and Canada's QLT (Vancouver). CLINICA -World Medical Device & Diagnostic News FILED 5 November 2001 COPYRIGHT 2001 PJB Publications Ltd
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.